Shuttle Pharma Announces Results Of Pre-IND Meeting With FDA For Ropidoxuridine Phase II Clinical Trial For Patients With Glioblastoma
Portfolio Pulse from Benzinga Newsdesk
Shuttle Pharma has announced the results of its pre-IND meeting with the FDA for the Phase II clinical trial of Ropidoxuridine for patients with Glioblastoma. The company is on track to initiate the clinical trial in Q4 of 2023.
September 25, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Shuttle Pharma's announcement of the successful pre-IND meeting with the FDA and the planned initiation of the Phase II clinical trial in Q4 2023 could potentially have a positive impact on the company's stock.
The successful pre-IND meeting with the FDA is a significant regulatory milestone for Shuttle Pharma. This, coupled with the company's announcement that it remains on track to initiate the Phase II clinical trial in Q4 2023, could potentially boost investor confidence and have a positive impact on the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100